Peteha's main active ingredient is Prothionamide, which is often used in combination with other drugs in the regimen to treat multi-resistant tuberculosis. The mechanism of action of the drug is to inhibit the synthesis of mycolic acid in the bacterial cell wall.

Drug-resistant tuberculosis is a public health crisis and a global health security threat with serious consequences for those affected. Treatment of drug-resistant or rifampicin-resistant tuberculosis requires a combination of different second-line drugs and a treatment duration of 18 months or more.

The main cause of drug-resistant tuberculosis is patient non-compliance with treatment regimens. Currently, Vietnam is one of 30 countries with a high burden of drug-resistant tuberculosis in the world. Although there have been some significant achievements in the prevention of tuberculosis in general and drug-resistant tuberculosis in particular, drug-resistant tuberculosis remains a global concern.

Currently, diagnosing tuberculosis in children is still difficult due to non-specific symptoms and low detection rate of tuberculosis bacteria by paraclinical tests. Treatment of children with tuberculosis needs to be carried out according to the treatment regimen and as soon as possible.